Johnson & Johnson suspends mid-term trial of experimental eczema drug

阿斯達克財經網
2025.12.26 17:58

強生 (JNJ.US) 週五表示，由於其用於治療中度至重度異位性皮膚炎 (濕疹) 患者的試驗性藥物在中期分析中未能達到療效目標，因此已停止該藥物的中期研究。

公司指，該藥物 JNJ-5939 正在濕疹患者身上進行測試，結果顯示耐受性良好，但未達到推進研發所需的高標準療效。

Source: 阿斯達克財經網 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.